- Home
- ABL vs COLL Comparison
ABL vs COLL Comparison
Compare ABL & COLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ABL
- COLL
- Stock Information
- Founded
- ABL 2004
- COLL 2002
- Country
- ABL United States
- COLL United States
- Employees
- ABL N/A
- COLL 357
- Industry
- ABL Investment Managers
- COLL Biotechnology: Pharmaceutical Preparations
- Sector
- ABL Finance
- COLL Health Care
- Exchange
- ABL Nasdaq
- COLL Nasdaq
- Market Cap
- ABL 853.6M
- COLL 947.6M
- IPO Year
- ABL N/A
- COLL 2015
- Fundamental
- Price
- ABL $7.73
- COLL $29.14
- Analyst Decision
- ABL Strong Buy
- COLL Strong Buy
- Analyst Count
- ABL 4
- COLL 5
- Target Price
- ABL $13.63
- COLL $43.80
- AVG Volume (30 Days)
- ABL 453.4K
- COLL 304.8K
- Earning Date
- ABL 05-08-2025
- COLL 05-08-2025
- Dividend Yield
- ABL N/A
- COLL N/A
- EPS Growth
- ABL N/A
- COLL N/A
- EPS
- ABL N/A
- COLL 1.25
- Revenue
- ABL $134,575,948.00
- COLL $664,283,000.00
- Revenue This Year
- ABL $65.34
- COLL $20.00
- Revenue Next Year
- ABL $25.72
- COLL $3.74
- P/E Ratio
- ABL N/A
- COLL $23.23
- Revenue Growth
- ABL 73.39
- COLL 17.17
- 52 Week Low
- ABL $6.34
- COLL $23.23
- 52 Week High
- ABL $12.40
- COLL $42.29
- Technical
- Relative Strength Index (RSI)
- ABL 34.93
- COLL 53.67
- Support Level
- ABL $7.90
- COLL $28.78
- Resistance Level
- ABL $8.50
- COLL $29.57
- Average True Range (ATR)
- ABL 0.28
- COLL 0.79
- MACD
- ABL -0.15
- COLL -0.03
- Stochastic Oscillator
- ABL 9.49
- COLL 36.56
About ABL Abacus Life Inc.
Abacus Global Management Inc is a financial services company specializing in alternative asset management, data-driven wealth solutions, technology innovations, and institutional services. The Company organizes its business into five reportable segments Active Management, Originations, Asset Management, Portfolio Servicing, and Technology Services. Its operations are confined to the United States.
About COLL Collegium Pharmaceutical Inc.
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Jornay, Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.